Navigation Links
National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine

MOUNTAINSIDE, N.J., July 17 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI) today announced that its wholly owned subsidiary Proteoderm, Inc. is exhibiting at the 16th Annual International World Congress on Anti-Aging Medicine being held in Washington, DC on July 17 -- 19, 2008. Dr. Kenneth Steiner, MD, MBA was invited to speak as a scientific keynote panelist. Dr. Steiner will introduce the company's first commercial line of cosmoceuticals, which will be sold through medical sales representatives for use by dermatologists, plastic surgeons and other licensed health care professionals.

Proteoderm licenses patented technologies involving stem cells and their derivatives developed by National Stem Cell Holding, Inc. Proteoderm produces, designs and synthesizes proteins, polypeptides and growth hormones secreted by stem cells trademarked under Secreted Matrix(TM) and Matrix NC 138(TM) and incorporates them into uniquely formulated personal care products.

Proteoderm has created an anti-aging and anti-wrinkle product line that enhances the skin's firmness and elasticity and promotes the skin's natural moisture production activity. Unlike the array of products on the market today that reduce the appearance of wrinkles by artificial moisturizing and plumping, Proteoderm's products are the first to provide Matrix NC 138(TM) to the skin surface. Proteoderm's cosmoceutical kits will contain day and night creams and an under-eye serum containing the patented Matrix NC 138(TM) as well as an exfoliant and a cleanser.

Dr. Steiner stated, "During pregnancy, the human body increases the production specific proteins in response to secretions produced by stem cells. These specific proteins are known to effect specific receptors in the skin that enhance the production of facial collagen. Proteoderm has developed compositions including topical formulations containing these naturally occurring proteins which assist in counteracting the adverse consequences of aging."

"We are very excited to commercialize Proteoderm's first line of cosmoceuticals. We look forward to enhancing shareholders' value as we introduce our unique product. This is a turning point in the maturation of our company," said CEO of National Stem Cell Holding, Inc. Michael Cohen.


About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a biotechnology company focused on the development and commercialization of cell therapeutics primarily for diabetes and cardiac disease, and cosmetics derived from stem cells. For more information, visit, and

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products and products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


Michael Cohen

Phone: (973) 544-6116

SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):